JP2014530818A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530818A5
JP2014530818A5 JP2014535757A JP2014535757A JP2014530818A5 JP 2014530818 A5 JP2014530818 A5 JP 2014530818A5 JP 2014535757 A JP2014535757 A JP 2014535757A JP 2014535757 A JP2014535757 A JP 2014535757A JP 2014530818 A5 JP2014530818 A5 JP 2014530818A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
methyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014535757A
Other languages
English (en)
Japanese (ja)
Other versions
JP6002228B2 (ja
JP2014530818A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/058824 external-priority patent/WO2013055577A1/en
Publication of JP2014530818A publication Critical patent/JP2014530818A/ja
Publication of JP2014530818A5 publication Critical patent/JP2014530818A5/ja
Application granted granted Critical
Publication of JP6002228B2 publication Critical patent/JP6002228B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014535757A 2011-10-13 2012-10-05 選択的アンドロゲン受容体調節剤 Active JP6002228B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546711P 2011-10-13 2011-10-13
US61/546,711 2011-10-13
PCT/US2012/058824 WO2013055577A1 (en) 2011-10-13 2012-10-05 Selective androgen receptor modulators

Publications (3)

Publication Number Publication Date
JP2014530818A JP2014530818A (ja) 2014-11-20
JP2014530818A5 true JP2014530818A5 (cg-RX-API-DMAC10.html) 2015-11-12
JP6002228B2 JP6002228B2 (ja) 2016-10-05

Family

ID=47046879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535757A Active JP6002228B2 (ja) 2011-10-13 2012-10-05 選択的アンドロゲン受容体調節剤

Country Status (28)

Country Link
US (1) US8658693B2 (cg-RX-API-DMAC10.html)
EP (1) EP2766350B1 (cg-RX-API-DMAC10.html)
JP (1) JP6002228B2 (cg-RX-API-DMAC10.html)
KR (1) KR20140067102A (cg-RX-API-DMAC10.html)
CN (1) CN103842348B (cg-RX-API-DMAC10.html)
AP (1) AP2014007548A0 (cg-RX-API-DMAC10.html)
AR (1) AR088082A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012321113B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014008668A2 (cg-RX-API-DMAC10.html)
CA (1) CA2847889A1 (cg-RX-API-DMAC10.html)
CL (1) CL2014000895A1 (cg-RX-API-DMAC10.html)
CO (1) CO6910195A2 (cg-RX-API-DMAC10.html)
CR (1) CR20140156A (cg-RX-API-DMAC10.html)
DO (1) DOP2014000075A (cg-RX-API-DMAC10.html)
EA (1) EA201490519A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP14013305A (cg-RX-API-DMAC10.html)
ES (1) ES2626820T3 (cg-RX-API-DMAC10.html)
GT (1) GT201400067A (cg-RX-API-DMAC10.html)
IL (1) IL231440A0 (cg-RX-API-DMAC10.html)
MX (1) MX2014004558A (cg-RX-API-DMAC10.html)
PE (1) PE20141669A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014500808A1 (cg-RX-API-DMAC10.html)
PL (1) PL2766350T3 (cg-RX-API-DMAC10.html)
PT (1) PT2766350T (cg-RX-API-DMAC10.html)
SG (1) SG11201401794YA (cg-RX-API-DMAC10.html)
TN (1) TN2014000136A1 (cg-RX-API-DMAC10.html)
TW (1) TWI449686B (cg-RX-API-DMAC10.html)
WO (1) WO2013055577A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
TW201534586A (zh) * 2013-06-11 2015-09-16 Orion Corp 新穎cyp17抑制劑/抗雄激素劑
ES2693520T3 (es) 2013-12-04 2018-12-12 Evotec International Gmbh Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
US10167296B2 (en) 2014-05-07 2019-01-01 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
PE20190475A1 (es) 2016-08-15 2019-04-04 Pfizer Inhibidores de cdk2/4/6
AU2017319609B2 (en) 2016-09-02 2019-11-14 Suven Life Sciences Limited Muscarinic M1 receptor positive allosteric modulators
US11076596B2 (en) 2017-09-18 2021-08-03 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
US11739075B2 (en) * 2020-06-24 2023-08-29 Celgene Corporation Cereblon binding compounds, compositions thereof, and methods of treatment therewith
WO2025104624A1 (en) * 2023-11-14 2025-05-22 Pfizer Inc. Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594405A (en) * 1968-05-17 1971-07-20 Du Pont Substituted pyranyl anilines as plant growth modifiers
ATE315555T1 (de) * 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US7807691B2 (en) * 2005-05-13 2010-10-05 Eli Lilly And Company Substituted N-arylpyrrolidines as selective androgen receptor modulators
EP1955697B1 (en) * 2005-11-30 2012-05-02 Astellas Pharma Inc. 2-aminobenzamide derivatives as vanilloid receptor 1 (vr1) inhibitors useful for the treatment of pain or bladder function disorder
US20080269193A1 (en) * 2007-04-16 2008-10-30 Kenneth He Huang Tetrahydroindole and Tetrahydroindazole Derivatives
US8190467B2 (en) * 2007-10-19 2012-05-29 Michelle Letendre-Hedlund Methods of identifying environmentally friendly businesses or individuals
US8067448B2 (en) * 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators

Similar Documents

Publication Publication Date Title
JP2014530818A5 (cg-RX-API-DMAC10.html)
JP2021530565A5 (cg-RX-API-DMAC10.html)
JP2019524883A5 (cg-RX-API-DMAC10.html)
JP2018035160A5 (cg-RX-API-DMAC10.html)
CN113784970A (zh) Erk抑制剂及其应用
JP2016501221A5 (cg-RX-API-DMAC10.html)
JP2011529054A5 (cg-RX-API-DMAC10.html)
JP2015537020A5 (cg-RX-API-DMAC10.html)
JP2013509429A5 (cg-RX-API-DMAC10.html)
JP2013522326A5 (cg-RX-API-DMAC10.html)
JP2020097577A5 (cg-RX-API-DMAC10.html)
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
JP2020511467A5 (cg-RX-API-DMAC10.html)
JP2013032389A5 (cg-RX-API-DMAC10.html)
JP2016534063A5 (cg-RX-API-DMAC10.html)
JP2016065042A5 (cg-RX-API-DMAC10.html)
JP2014515013A5 (cg-RX-API-DMAC10.html)
JP2010001302A5 (cg-RX-API-DMAC10.html)
JP2013512277A5 (cg-RX-API-DMAC10.html)
JP2011527299A5 (cg-RX-API-DMAC10.html)
JP2017517565A5 (cg-RX-API-DMAC10.html)
JP2014511374A5 (cg-RX-API-DMAC10.html)
JP2013503134A5 (cg-RX-API-DMAC10.html)
RU2015134420A (ru) Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты
JP2015522037A5 (cg-RX-API-DMAC10.html)